RUBINSTEIN JULIE sold $920K of ADPT

RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.81 ($25.35–$26.41, $0.92M total) across 4 trades over 2026-10-09 to 2026-10-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RUBINSTEIN JULIE
Published Oct 13, 2026, 11:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Bearish
high confidence
Mentioned
$ADPT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

The disclosed sale may cause short‑term price pressure but is unlikely to affect long‑term valuation.

02

Market read

Primary insider sale filing; modest relevance for traders monitoring insider activity.

03

What to watch

The 10b5‑1 plan indicates pre‑planned execution, reducing the signaling strength.

Relevance 4/10Novelty 4/10Timing: today

Background

SEC Form 4 filings disclose insider transactions. This filing reports a multi‑day sale by the company's President and COO.

Company-level read

Ticker impact

$ADPTBearishHigh confidence
Context

Form 4 filing shows President and COO Julie Rubinstein sold 35,643 shares for $919.9K via a 10b5‑1 plan.

Expected impact

likely modest pressure as the market prices in the insider sell.

Evidence & confidence

The sale is a primary disclosure of a sizable insider transaction, albeit under $1M, which can prompt short‑term selling pressure.

Market effects

Minimal impact on the biotech sector; insider sales are routine.

No broader regional effect.

Limited to Adaptive Biotechnologies shareholders.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • Adaptive Biotechnologies Corp

    US‑listed biotech firm (NASDAQ: ADPT).

  • Julie Rubinstein

    President and COO of Adaptive Biotechnologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.